Are There Any Differences in the Prognostic Value of Left Ventricular Ejection Fraction in Coronary Artery Disease Patients With or Without Moderate and Severe Mitral Regurgitation?

Qiang Li, Yifei Zhang, Haozhang Huang, Weihua Chen, Shanshan Shi, Shiqun Chen, Bo Wang, Wenguang Lai, Zhidong Huang, Zhiling Luo, Jiyan Chen, Ning Tan, Jin Liu, Yong LiuFrontiers in Cardiovascular Medicine 2022 · DOI

TL;DR

This study investigates whether Left Ventricular Ejection Fraction (LVEF), a standard measure of heart pumping efficiency, remains a reliable predictor of long-term survival in patients with Coronary Artery Disease (CAD) who also have moderate to severe Mitral Regurgitation (MR). The findings confirm that LVEF is indeed a valuable prognostic indicator even in the presence of MR, suggesting continued clinical utility for LVEF monitoring in these complex patient populations.

What Problem Does This Paper Address?

Coronary Artery Disease (CAD) is a leading cause of mortality worldwide, and Left Ventricular Ejection Fraction (LVEF) is a crucial metric for assessing cardiac function and predicting outcomes in these patients. Mitral Regurgitation (MR), a condition where the mitral valve doesn't close properly, is also common in CAD patients and significantly increases mortality risk. However, the presence of moderate to severe MR can complicate the interpretation of LVEF, potentially overestimating a patient's actual cardiac function due to volume overload. This has led to a debate about whether LVEF remains a reliable prognostic tool in CAD patients with significant MR. This paper aims to clarify this by examining the association between LVEF and long-term prognosis across different severities of MR.

Methods

The researchers conducted a retrospective cohort study using data from the Cardiorenal ImprovemeNt (CIN) registry, which included over 30,000 patients diagnosed with CAD. Patients were categorized based on the severity of their mitral regurgitation: "none or mild MR" versus "moderate or severe MR." Within these groups, LVEF was further stratified into three levels: ≥50% (normal), 40-50% (mild dysfunction), and <40% (moderate or severe dysfunction). The primary outcome of interest was long-term all-cause mortality. To assess the relationship between LVEF and mortality, both univariate and multivariate Cox proportional hazard analyses were employed. The multivariate models progressively adjusted for a comprehensive set of confounding factors, including demographic characteristics, comorbidities (like hypertension, diabetes, heart failure, etc.), and medications.

Datasets

The study utilized data from the Cardiorenal ImprovemeNt (CIN) registry, a single-center observational cohort study. The dataset comprised 30,775 patients with Coronary Artery Disease (CAD) who underwent coronary arteriography between January 2007 and December 2018. Patient follow-up data for mortality was obtained from the Guangdong Provincial Public Security and matched with the hospital's electronic Clinical Management System. No new datasets were introduced.

Key Insights and Ideas

  • LVEF's Enduring Prognostic Power: Despite concerns that MR might obscure LVEF's predictive ability, this study strongly suggests that LVEF remains a robust indicator of prognosis in CAD patients, irrespective of MR severity. This is a critical finding for clinical practice.
  • Consistent Risk Association: The study found that a lower LVEF (<40%) consistently predicted a higher risk of all-cause death in both the "none or mild MR" and "moderate or severe MR" groups, even after extensive adjustment for confounding factors.
  • Clinical Utility Despite MR: The results reinforce the idea that LVEF monitoring is not only useful but clinically essential for risk stratification and guiding treatment decisions in CAD patients, even those with moderate to severe mitral regurgitation.

Key Results

The study analyzed 30,775 CAD patients. Of these, 26,474 (86.0%) had none or mild MR, and 4,301 (14.0%) had moderate or severe MR.

  • Kaplan-Meier Curves: Both groups showed a clear trend where lower LVEF levels were associated with higher cumulative mortality over an 8-year follow-up period (log-rank test, p < 0.001 for both groups).
  • Multivariate Cox Analysis (Model 3 - fully adjusted):
    • In patients with none or mild MR, LVEF < 40% was associated with a significantly higher risk of all-cause death compared to LVEF ≥ 50% (adjusted Hazard Ratio [HR]: 1.79; 95% CI: 1.56–2.05, p < 0.001).
  • In patients with moderate or severe MR, LVEF < 40% was also significantly associated with a higher risk of all-cause death compared to LVEF ≥ 50% (adjusted HR: 1.57; 95% CI: 1.29–1.91, p < 0.001).
  • Interaction Analysis: The study found no statistically significant interaction between LVEF and MR severity (p = 0.29), further supporting that LVEF's prognostic value is consistent across MR severities.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-Center Retrospective Design: This design inherently limits the ability to control for all potential confounders and introduces the possibility of selection bias.
  • Population Selection Bias: The study excluded patients from primary hospitals, potentially limiting generalizability.
  • Lack of Dynamic LVEF Monitoring: The study relied on baseline LVEF measurements. Monitoring dynamic changes in LVEF over time might offer more crucial prognostic information.
  • No Cause-Specific Death Data: The analysis focused on all-cause mortality, and the specific causes of death were not available, which could limit a deeper understanding of LVEF's role in different disease trajectories.

The authors suggest that clinical trials are needed to prospectively evaluate the optimal threshold for LVEF in patients with moderate or severe MR. They also emphasize the importance of continued LVEF monitoring and its role in guiding therapeutic decisions, particularly for patients with moderate to severe MR where interventions like mitral valve surgery might be considered.

Summary updated

Abstract

LVEF is a reliable prognostic index in CAD patients, even in those with moderate or severe MR. LVEF monitoring would still be clinically useful in CAD patients with moderate or severe MR. Clinical trials are needed to prospectively evaluate the optimal threshold for LVEF in patients with moderate or severe MR.
BibTeX
@inproceedings{li2022are,
  author = {Qiang Li and Yifei Zhang and Haozhang Huang and Weihua Chen and Shanshan Shi and Shiqun Chen and Bo Wang and Wenguang Lai and Zhidong Huang and Zhiling Luo and Jiyan Chen and Ning Tan and Jin Liu and Yong Liu},
  title = {{Are There Any Differences in the Prognostic Value of Left Ventricular Ejection Fraction in Coronary Artery Disease Patients With or Without Moderate and Severe Mitral Regurgitation?}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.799253},
}
Figure